Utama › Leukemia
Kajian klinikal Leukemia sedang mengambil peserta di AS
102 kajian untuk Leukemia sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX28 kajian
- Boston, MA25 kajian
- New York City, NY19 kajian
- Los Angeles, CA16 kajian
- Chicago, IL16 kajian
- Durham, NC13 kajian
- Columbus, OH12 kajian
- Nashville, TN12 kajian
- Baldwin Park, CA12 kajian
- Philadelphia, PA12 kajian
- Milwaukee, WI11 kajian
- Atlanta, GA11 kajian
- Seattle, WA11 kajian
- Birmingham, AL10 kajian
- Aurora, CO10 kajian
- Edison, NJ9 kajian
- Mountain View, CA9 kajian
- Miami, FL9 kajian
- Cincinnati, OH9 kajian
- Portland, OR8 kajian
- Queens, NY8 kajian
- Dallas, TX8 kajian
- New Haven, CT8 kajian
- Buffalo, NY7 kajian
- Denver, CO7 kajian
- Washington, DC7 kajian
- Tampa, FL7 kajian
- Orange, CA7 kajian
- Clifton, NJ7 kajian
- Cedar Rapids, IA6 kajian
- Omaha, NE6 kajian
- Ann Arbor, MI5 kajian
- Baltimore, MD5 kajian
- Charlottesville, VA5 kajian
- Memphis, TN5 kajian
- Rochester, MN5 kajian
- Cleveland, OH5 kajian
- San Diego, CA5 kajian
- Charlotte, NC5 kajian
- Rochester, NY4 kajian
Mengikut negeri
- Alabama10 kajian
- Arizona7 kajian
- California28 kajian
- Colorado15 kajian
- Connecticut11 kajian
- Florida17 kajian
- Georgia13 kajian
- Illinois17 kajian
- Indiana4 kajian
- Iowa7 kajian
- Kansas5 kajian
- Kentucky6 kajian
- Louisiana3 kajian
- Maine3 kajian
- Maryland11 kajian
- Massachusetts28 kajian
- Michigan8 kajian
- Minnesota9 kajian
- Missouri6 kajian
- Nebraska6 kajian
- New Jersey15 kajian
- New Mexico3 kajian
- New York26 kajian
- North Carolina20 kajian
- Ohio26 kajian
- Oklahoma4 kajian
- Oregon9 kajian
- Pennsylvania15 kajian
- Rhode Island4 kajian
- South Carolina6 kajian
- Tennessee14 kajian
- Texas31 kajian
- Utah4 kajian
- Vermont4 kajian
- Virginia7 kajian
- Washington11 kajian
- Wisconsin13 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Rutgers University Study of the Genetics of Blood Cancers
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 110 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT00923507Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Mengambil pesertaFasa 3
Umur 18 hingga 71 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Mengambil pesertaFasa 2
Umur 1 hingga 25 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 2 hingga 100 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT01905826A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06824168A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Mengambil pesertaFasa 1
Sehingga umur 25 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Mengambil pesertaFasa 2
Umur 1 hingga 18 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07354074Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Mengambil pesertaFasa 1
Umur 1 hingga 25 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06408194First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07586618Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 5 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT05237986CIML NK Cells With Venetoclax for AML
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT06152809Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07284433Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Mengambil pesertaFasa 1
Umur 18 hingga 90 · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Mengambil pesertaFasa 1
18 Months – 39 Years · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT07573111Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.